R.H. Bluestein & Co’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $566K | Sell |
5,163
-125
| -2% | -$15.9K | 0.04% | 135 |
|
|
2022
Q2 | $699K | Buy |
5,288
+125
| +2% | +$16.4K | 0.04% | 131 |
|
|
2022
Q1 | $685K | Sell |
5,163
-1,500
| -23% | -$180K | 0.03% | 148 |
|
|
2021
Q4 | $776K | Sell |
6,663
-1,000
| -13% | -$118K | 0.03% | 142 |
|
|
2021
Q3 | $920K | Buy |
7,663
+968
| +14% | +$113K | 0.04% | 123 |
|
|
2021
Q2 | $802K | Buy |
6,695
+32
| +0.5% | +$3.51K | 0.03% | 158 |
|
|
2021
Q1 | $663K | Sell |
6,663
-3,000
| -31% | -$302K | 0.03% | 161 |
|
|
2020
Q4 | $966K | Buy |
9,663
+2,500
| +35% | +$265K | 0.04% | 103 |
|
|
2020
Q3 | $785K | Buy |
7,163
+500
| +8% | +$55.6K | 0.04% | 111 |
|
|
2020
Q2 | $705K | Sell |
6,663
-50
| -0.7% | -$5.16K | 0.04% | 116 |
|
|
2020
Q1 | $600K | Sell |
6,713
-950
| -12% | -$89.4K | 0.05% | 105 |
|
|
2019
Q4 | $764K | Hold |
7,663
| – | – | 0.04% | 112 |
|
|
2019
Q3 | $683K | Hold |
7,663
| – | – | 0.04% | 110 |
|
|
2019
Q2 | $633K | Hold |
7,663
| – | – | 0.03% | 118 |
|
|
2019
Q1 | $620K | Hold |
7,663
| – | – | 0.03% | 103 |
|
|
2018
Q4 | $582K | Hold |
7,663
| – | – | 0.05% | 91 |
|
|
2018
Q3 | $606K | Sell |
7,663
-100
| -1% | -$7.56K | 0.03% | 138 |
|
|
2018
Q2 | $545K | Buy |
7,763
+100
| +1% | +$7.19K | 0.03% | 144 |
|
|
2018
Q1 | $536K | Sell |
7,663
-537
| -7% | -$37.2K | 0.03% | 146 |
|
|
2017
Q4 | $569K | Buy |
8,200
+650
| +9% | +$43.8K | 0.03% | 135 |
|
|
2017
Q3 | $512K | Sell |
7,550
-22,125
| -75% | -$1.4M | 0.03% | 154 |
|
|
2017
Q2 | $2.02M | Buy |
29,675
+9,050
| +44% | +$591K | 0.12% | 54 |
|
|
2017
Q1 | $1.28M | Sell |
20,625
-36,150
| -64% | -$2.1M | 0.08% | 63 |
|
|
2016
Q4 | $3.1M | Sell |
56,775
-112,075
| -66% | -$6.36M | 0.2% | 45 |
|
|
2016
Q3 | $11.1M | Buy |
168,850
+154,850
| +1,106% | +$10.1M | 0.73% | 37 |
|
|
2016
Q2 | $845K | Sell |
14,000
-2,500
| -15% | -$145K | 0.06% | 66 |
|
|
2016
Q1 | $929K | Buy |
16,500
+1,500
| +10% | +$90.1K | 0.07% | 77 |
|
|
2015
Q4 | $1.02M | Hold |
15,000
| – | – | 0.06% | 77 |
|
|
2015
Q3 | $955K | Sell |
15,000
-14,050
| -48% | -$924K | 0.07% | 82 |
|
|
2015
Q2 | $1.85M | Sell |
29,050
-34,995
| -55% | -$2.4M | 0.11% | 60 |
|
|
2015
Q1 | $4.38M | Sell |
64,045
-45,150
| -41% | -$3.14M | 0.26% | 52 |
|
|
2014
Q4 | $7.68M | Buy |
109,195
+99,195
| +992% | +$7.1M | 0.48% | 52 |
|
|
2014
Q3 | $714K | Hold |
10,000
| – | – | 0.04% | 140 |
|
|
2014
Q2 | $743K | Sell |
10,000
-8,000
| -44% | -$578K | 0.04% | 146 |
|
|
2014
Q1 | $1.17M | Sell |
18,000
-2,000
| -10% | -$129K | 0.08% | 101 |
|
|
2013
Q4 | $1.19M | Sell |
20,000
-2,000
| -9% | -$109K | 0.07% | 97 |
|
|
2013
Q3 | $1.14M | Hold |
22,000
| – | – | 0.08% | 96 |
|
|
2013
Q2 | $1.04M | Buy |
+22,000
| New | +$1.12M | 0.09% | 98 |
|
Other funds holding AZN
R.H. Bluestein & Co's AZN Position: Q3 2022 in Review
R.H. Bluestein & Co reduced its AstraZeneca (AZN) stake by 2.4% in Q3 2022, selling an estimated $15.9K and leaving 5,163 shares worth $566K. The position accounts for 0.04% of the portfolio, ranked #135.
R.H. Bluestein & Co first reported a position in AZN in Q2 2013 and has held it in 38 quarters since. The position peaked at $11.1M in Q3 2016. 965 funds tracked by Wall St. Rank hold AZN as of Q3 2022.
- R.H. Bluestein & Co held 5,163 shares of AstraZeneca worth $566K as of Q3 2022.
- R.H. Bluestein & Co sold 125 AstraZeneca shares in Q3 2022, an estimated $15.9K.
- AstraZeneca made up 0.04% of R.H. Bluestein & Co's portfolio in Q3 2022, its #135 holding.
- R.H. Bluestein & Co first reported a position in AstraZeneca in Q2 2013 and has held it in 38 quarters since.
- R.H. Bluestein & Co's AstraZeneca position peaked at $11.1M in Q3 2016.
- 965 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2022.
Based on R.H. Bluestein & Co's 13F filing for Q3 2022, filed 14 Nov 2022.